Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder <l ...

INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg and 80 mg capsules. movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

In the KINECT-HD study, patients were randomized 1:1 to receive INGREZZA (n=64) at doses of 40 mg, 60 mg or 80 mg, or placebo (n=61). TMC scores at baseline were similar between treatment groups. Key ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent irrespective ...